The Booming Business Of Drug Exclusions
The number of drugs included on formulary exclusion lists in the US has surpassed more than 400 at the top three PBMs, representing dramatic growth from just five years ago. Express Scripts recently revealed its 2022 exclusions.
You may also be interested in...
Oncology drugs are no longer immune to pharmacy benefit management formulary exclusions in the commercial market and even drugs administered in a physician’s office are increasingly being subjected to rebate-driven coverage decisions.
In this week's podcast edition of Five Must-Know Things: new US warnings for JAK inhibitors; strong new heart failure results for Jardiance; good head-to-head results for Pfizer in atopic dermatitis; US payers and drug exclusion lists; and a look ahead at key expected hematology launches.
Amgen has once again touched on its impending expansion into US inflammation/immunology biosimilars, with launches for adalimumab and ustekinumab scheduled for the coming years.